Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Living a Life on Purpose: A Conversation with Dr. Randy

When people take stock of their lives, do they consider their accomplishments remarkable? Or is the word remarkable reserved only for those with unique talents and wondrous deeds? Maybe remarkable isn’t a word others use to describe a person; perhaps it’s a code to live by. Today, I choose to be Remarkable! Capitalize that…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

When people take stock of their lives, do they consider their accomplishments remarkable? Or is the word remarkable reserved only for those with unique talents and wondrous deeds? Maybe remarkable isn’t a word others use to describe a person; perhaps it’s a code to live by. Today, I choose to be Remarkable! Capitalize that R and add an exclamation point to it. That mantra comes from a man who made it his mission to live his life on purpose. To be remarkable, Dr. Randy Ross says, choose to be Remarkable!

Inspiring and influencing others is a key differentiator in leadership, and motivating teams can make a good organization great. Dr. Randy Ross is a bestselling author and CEO of Remarkable. He brings his dynamic communication approach to organizations such as Delta, Chick-fil-A, McDonald’s, Panasonic, and more to help strengthen team development and organizational health.

Ross spoke with I Don’t Care’s Kevin Stevenson about his career and his love for working with organizations and leadership to improve them. Ross, a pastor for many years, felt a new calling the more he worked with business leaders.

“I fell in love with the boardroom,” Ross said. “I felt called into corporate circles because I saw this interesting disparity, this paradox if you will; so many organizations struggled to embrace this idea of culture in a profound way. They knew the importance of it, but they didn’t know how to craft it.”

Stevenson and Ross discuss the following:

  • Connecting personal passion with corporate objectives
  • The concept of “anchored by hope”
  • Ross’s book Relationomics

“I wanted to write a book that would be a practical ‘how to,’” Dr. Ross said. “We kind of built the framework for the principals, but now how do you do this? How do you put it into practice? So, Relationomics is a book I wrote for managers and anybody who gives oversight to others. And it is a lot of practical things that you and I might say is common sense, but I can assure you it is not always common practice.”

About Randy:

Dr. Randy Ross is the bestselling author of multiple books, including Relationomics: Business Powered by Relationships, Remarkable!, and Hope Rises: Making Your Life, Love & Leadership Soar. Ross works with known brands to inspire and enable countless people to find new passion and purpose in their work, work better together in teams, and have more significant influence and impact. He holds a B.A. in Philosophy and Religion from Baylor University and a Doctorate from Southwestern Baptist Theological Seminary.

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Microsoft’s 60% Dragon Copilot discount forces a new way to measure digital health ROI

Microsoft’s 60% Dragon Copilot discount forces a new way to measure digital health ROI

Microsoft has introduced a 60% discount for its Dragon Copilot, prompting a reevaluation of how digital health ROI is measured. The initiative targets rural hospitals, while European efforts like EDiHTA highlight the need for a consistent method to price technology evidence. This shift reflects a broader trend in healthcare towards data-driven decision-making and cost assessment.

  • 01Microsoft offers a 60% discount for Dragon Copilot aimed at rural hospitals.
  • 02There's a growing need for a standardized approach to pricing technology evidence in healthcare.
  • 03The European EDiHTA initiative exemplifies the trend of data-driven evaluation in digital health.

Aug 30, 2026

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512